CG
RYTM icon

Cutler Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Cutler Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$47K Buy
1,100
+600
+120% +$26.3K 0.02% 703
2023
Q4 		$22K Buy
+500
New +$15.8K ﹤0.01% 1924
2023
Q2 		– Sell
-100
Closed -$1.8K – 4105
2023
Q1 		$1K Buy
+100
New +$2.51K ﹤0.01% 3541
2022
Q4 		– Sell
-1,000
Closed -$25.7K – 5095
2022
Q3 		$24K Sell
1,000
-336
-25% -$6.25K ﹤0.01% 2485
2022
Q2 		$5K Sell
1,336
-500
-27% -$2.74K ﹤0.01% 3754
2022
Q1 		$21K Buy
+1,836
New +$16.1K ﹤0.01% 3034
2021
Q3 		– Sell
-7,418
Closed -$145K – 6271
2021
Q2 		$145K Sell
7,418
-784
-10% -$16.3K 0.01% 1568
2021
Q1 		$174K Buy
8,202
+3,502
+75% +$102K 0.01% 1371
2020
Q4 		$139K Sell
4,700
-700
-13% -$17.8K 0.01% 1309
2020
Q3 		$117K Buy
5,400
+4,500
+500% +$103K 0.01% 1225
2020
Q2 		$20K Buy
+900
New +$17.5K ﹤0.01% 2392
2020
Q1 		– Sell
-100
Closed -$1.79K – 4549
2019
Q4 		$2K Sell
100
-100
-50% -$2.22K ﹤0.01% 3489
2019
Q3 		$4K Hold
200
– – ﹤0.01% 3195
2019
Q2 		$4K Buy
+200
New +$5.05K ﹤0.01% 3253

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Cutler Group's RYTM Position: Q1 2024 in Review

Cutler Group increased its Rhythm Pharmaceuticals (RYTM) stake by 120% in Q1 2024, buying an estimated $26.3K and bringing the position to 1,100 shares worth $47K. The position accounts for 0.02% of the portfolio, ranked #703.

Cutler Group first reported a position in RYTM in Q2 2019 and has held it in 14 quarters since. The position peaked at $174K in Q1 2021. 167 funds tracked by Wall St. Rank hold RYTM as of Q1 2024.

  • Cutler Group held 1,100 shares of Rhythm Pharmaceuticals worth $47K as of Q1 2024.
  • Cutler Group bought 600 Rhythm Pharmaceuticals shares in Q1 2024, an estimated $26.3K.
  • Rhythm Pharmaceuticals made up 0.02% of Cutler Group's portfolio in Q1 2024, its #703 holding.
  • Cutler Group first reported a position in Rhythm Pharmaceuticals in Q2 2019 and has held it in 14 quarters since.
  • Cutler Group's Rhythm Pharmaceuticals position peaked at $174K in Q1 2021.
  • 167 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.